Motion Serifos: A Study to Investigate the Efficacy of Tradipitant in Participants Affected by Motion Sickness
NCT ID: NCT05903924
Last Updated: 2025-04-04
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
316 participants
INTERVENTIONAL
2023-09-09
2024-04-24
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Motion Sifnos: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion Sickness
NCT03772340
Motion Syros: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion Sickness
NCT04327661
Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness
NCT06138613
Prevention and Treatment of Nausea Associated With Motion Sickness in Senior Subjects
NCT03988530
The Prevention and Treatment of Nausea Associated With Motion Sickness
NCT03986905
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Tradipitant High Dose
Tradipitant
Oral Capsule
Placebo
Placebo
Oral Capsule
Tradipitant Low Dose
Tradipitant
Oral Capsule
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Tradipitant
Oral Capsule
Placebo
Oral Capsule
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age 18-75
Exclusion Criteria
* BMI\>40
* History of intolerance and/or hypersensitivity to Neurokinin-1 Receptor antagonists
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Vanda Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pacific Research Partners
San Diego, California, United States
Lumos Clinical Research
San Jose, California, United States
Santa Monica Clinical Trials
Santa Monica, California, United States
Beacon Clinical Research
Boston, Massachusetts, United States
Manhattan Medical Research
New York, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
VP-VLY-686-3404
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.